Kissei Pharmaceutical Partners With Reborna Biosciences for Drug Discovery in Genetic Rare Diseases

Kissei Pharmaceutical (TYO:4547) and Reborna Biosciences have signed a research collaboration agreement for drug discovery in genetic rare diseases, according to a Tokyo Stock Exchange filing on Monday.

The collaboration will use Reborna's RNA-targeting small molecule drug discovery technology.

Kissei will provide upfront payments, research expenses, milestone payments, and royalties, and retain global development and commercialization rights for successful compounds.

Price (JPY): $3560.00, Change: $+20, Percent Change: +0.56%